Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

Official Title

A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination with Celecoxib and Gemcitabine in Patients with Malignant Pleural Mesothelioma

Details

Keywords

Malignant Pleural Mesothelioma, Mesothelioma, Malignant Mesothelioma, Celecoxib, Gemcitabine, rAd-IFN, Celecoxib Oral Product

Eligibility

Locations

  • UCSF (UCSF)
    San Francisco California 94158 United States
  • University of California, Los Angeles (UCLA) - Medical Center
    Los Angeles California 90059 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Ferring Ventures Limited
ID
NCT03710876
Phase
Phase 3 research study
Study Type
Interventional
Participants
About 53 people participating
Last Updated